KLOE-ba-zam
Contraindicated in:
Use Cautiously in:
Derm: DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), STEVENS-JOHNSON SYNDROME (SJS), TOXIC EPIDERMAL NECROLYSIS (TEN)
GI: constipation, drooling, dysphagia, vomiting
Neuro: sedation, somnolence, aggression, ataxia, dizziness, dysarthria, fatigue, insomnia, irritability, lethargy
Resp: cough
Misc:
physical dependence
,psychological dependence
Drug-drug:
Use with opioids or other CNS depressants, including other benzodiazepines, nonbenzodiazepine sedative/hypnotics, anxiolytics, general anesthetics, muscle relaxants, antipsychotics, and alcohol, may cause profound sedation, respiratory depression, coma, and death; reserve concurrent use for when alternative treatment options are inadequate.
Hepatic Impairment
Hepatic Impairment
Absorption: Well absorbed following oral administration.
Distribution: Rapidly distributes throughout the body.
Half-Life: Clobazam: 36–42 hr; desmethylclobazam: 71–82 hr.
Caution patient not to stop taking clobazam without consulting health care provider. Abrupt withdrawal may cause sweating, vomiting, muscle cramps, tremors, and seizures; may be life-threatening.
Advise patient to avoid the use of alcohol or other CNS depressants, including opioids, concurrently with clobazam; may cause respiratory depression and overdose. Instruct patient to consult health care provider before taking Rx, OTC, or herbal products concurrently with this medication, especially St. John's wort.
Advise patient that clobazam is a drug with known abuse potential. Protect it from theft, and never give to anyone other than the individual for whom it was prescribed. Store out of sight and reach of children, and in a location not accessible by others.
NDC Code